Protic, Marijana; Schoepfer, Alain; Yawalkar, Nikhil; Vavricka, Stephan; Seibold, Frank (2016). Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels. Scandinavian journal of gastroenterology, 51(12), pp. 1482-1488. Informa Healthcare 10.1080/00365521.2016.1218541
Text
PSORIASIS SJG (1).pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (923kB) |
BACKGROUND
The cause of anti-TNF-induced psoriasis is still unknown.
OBJECTIVE
We aimed to evaluate if the appearance of psoriasis under anti-TNF therapy is associated with anti-TNF antibody levels and TNF-antagonist trough levels.
METHODS
In this case-control study we identified 23 patients (21 with Crohn's disease [CD], two with ulcerative colitis [UC]) who developed psoriasis under infliximab (IFX, n = 20), adalimumab (ADA, n = 2), and certolizumab pegol (CZP, n= 1) and compared them regarding the anti-TNF-antagonist antibody levels with 85 IBD patients (72 with CD, 13 with UC) on anti-TNF therapy without psoriasis.
RESULTS
Median disease duration was not different between the two groups (7 years in the group with psoriasis under TNF-antagonists vs. 10 years in the control group, p = 0.072). No patient from the psoriasis group had antibodies against TNF-antagonists compared to 10.6% in the control group (p = 0.103). No difference was found in IFX trough levels in the group of patients with psoriasis compared to the control group (2.6 μg/mL [IQR 0.9-5.5] vs. 3.4 μg/mL [IQR 1.4-8.1], p = 0.573). TNF-antagonist therapy could be continued in 91.3% of patients with TNF-antagonist related psoriasis and most patients responded to topical therapies.
CONCLUSION
Anti-TNF-induced psoriasis seems to be independent of anti-TNF antibodies and trough levels. Interruption of Anti-TNF therapy is rarely necessary.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology |
UniBE Contributor: |
Yawalkar, Nikhil |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0036-5521 |
Publisher: |
Informa Healthcare |
Language: |
English |
Submitter: |
Andrea Studer-Gauch |
Date Deposited: |
14 Feb 2017 10:59 |
Last Modified: |
05 Dec 2022 15:01 |
Publisher DOI: |
10.1080/00365521.2016.1218541 |
PubMed ID: |
27534974 |
Uncontrolled Keywords: |
Crohn’s disease; Psoriasis; adalimumab; certolizumab pegol; inflammatory bowel disease; infliximab; ulcerative colitis |
BORIS DOI: |
10.7892/boris.93494 |
URI: |
https://boris.unibe.ch/id/eprint/93494 |